Group 1- Patients who received multiple treatments
88% cost reduction and 80% referral to clinical trials
# of patients recommended for standard therapies
# of patients recommended for clinical trials
50% of the patients decided to go to clinical trials identified by Massive Bio
- The total cost of drugs to insurance companies for 10 patients reduced from $517k to $61k as Massive Bio has identified clinical trials for 80% of the patients. The cost of drugs is absorbed by pharmaceutical companies which drove most of the cost reduction to the insurance.
- 50% of the patients decided to pursue the clinical trial as Massive Bio was taken patient’s preferences into account prior to trial matching process.
- For this group, tumor profiling costs were not considered because most of the patients already had their profiling results but they didn’t know how to use the results and integrate into their care plan.